BioSpace News Archive

InvoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that F-star, an invoX company, has entered into a second licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.

Cognito Therapeutics announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors.

Massive Bio, Inc. and NeoGenomics, Inc. today announced a collaboration with the goal of accelerating the development of new cancer therapies and ultimately improving the lives of millions of cancer patients around the world.

Astria Therapeutics today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Caraway Therapeutics today announced that the Company will be participating in the Stifel CNS Days event on March 29, 2023.

EpiBiologics launched today with $50 million in Series A funding.

DermBiont today announced that its Phase 2 adaptive design trial with of investigational drug SM-020 gel 1.0% met its primary endpoint of a one point improvement in Physician’s lesion assessment (PLA) score at last visit and safety via local tolerability, as well as key multiple secondary endpoints including complete clearance of treated lesions.

iECURE announced today that the European Commission granted orphan designation for the company’s lead product candidate GTP-506 for the treatment of Ornithine Transcarbamylase (OTC) deficiency.

NImmune Biopharma today announced its launch following the acquisition of omilancor, NIM-1324, and the entire LANCL portfolio of immunoregulatory therapeutic assets from Landos Biopharma, Inc.

Equillium, Inc. , today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference.